TNFRSF8 and Hodgkins lymphoma: Brentuximab vedotin (BV), an anti-CD30 antibody–drug conjugate (ADC), was FDA approved in 2011 for patients with R/R HL who have undergone autologous stem cell transplant or multiple chemotherapy regimens, based on a complete response (CR) rate of 34% and an overall duration of response of 5.6 months (20.5 months in those with CR; ref. 1).